वैकल्पिक उत्पाद विश्लेषण
आपकी अनुमति से हम गोपनीयता-सीमित विश्लेषण का उपयोग करके समझते हैं कि कौन-सी शोध यात्राएँ उपयोगी हैं। हम विज्ञापन ट्रैकर या सत्र रिकॉर्डिंग नहीं चलाते। आप यह विकल्प प्राथमिकताओं में बदल सकते हैं। पढ़ें गोपनीयता नीति.
HCA Healthcare Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $101.9B | |
|---|---|---|
| Revenue (ttm) | 78.7B | |
| Net income (ttm) | 6.8B | |
| EPS (ttm) | $30.2 | |
| Shares out | 216.5M | |
| P/E (trailing) | 15.3x | |
| P/E (forward) | 13.8x | |
| Dividend | $3.12 (0.68%) | |
| Volume | 1,798,814 | |
| Beta | 1.11 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $58.75B | $60.23B | $64.97B | $70.60B | $75.60B | +6.5% |
| Gross profit | $22.49B | $23.18B | $25.58B | $28.68B | $31.37B | +8.7% |
| Operating income | $11.40B | $10.32B | $9.64B | $10.58B | $12.08B | +1.5% |
| Net income | $6.96B | $5.64B | $5.24B | $5.76B | $6.78B | -0.6% |
| EPS (diluted) | $21.16 | $19.15 | $18.97 | $22.00 | $28.33 | +7.6% |
| EBITDA | $14.25B | $13.29B | $12.72B | $13.90B | $15.60B | +2.3% |
| R&D | — | — | — | — | — | — |
| SG&A | $26.78B | $27.69B | $29.49B | $31.17B | $8.00B | -26.1% |
Recent company headlines from major financial publishers.
The modal path reflects steady same-facility equivalent admission expansion supported by favorable Sunbelt demographic trends, tempered by gradual outpatient procedure migration. Operating margins remain stable as purchasing efficiencies through the group purchasing organization balance clinical wage pressures, while regular share repurchases funded by operational cash conversion drive compound per-share growth.
Under the upside trajectory, rapid demographic expansion in key Sunbelt metropolitan markets drives accelerated commercial admissions and a rebound in higher-acuity inpatient surgical procedures. Centralized purchasing scale and clinical workflow productivity contain operating expense inflation, expanding operating margins and enabling robust free cash flow to accelerate share repurchase execution.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 8.3% | $557 | $578 | $602 | $629 | $660 |
| 8.8% | $513 | $530 | $548 | $569 | $592 |
| 9.3% | $476 | $490 | $504 | $521 | $539 |
| 9.8% | $445 | $456 | $468 | $482 | $496 |
| 10.3% | $419 | $428 | $438 | $449 | $461 |
Upcoming earnings date and setup when available.
हर महीने प्रकाशित शोध संस्करण की रेटिंग। रेटिंग विश्लेषण की तारीख की कीमत की तुलना उचित मूल्य से करती है; यह इस बात का रिकॉर्ड नहीं है कि आकलन सही निकला या नहीं।
| वर्ष | जन॰ | फ़र॰ | मार्च | अप्रैल | मई | जून | जुल॰ | अग॰ | सित॰ | अक्टू॰ | नव॰ | दिस॰ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
